COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,950 Articles (22,604 medRxiv, 8,346 bioRxiv)

Most recent first Previous |  Page 285: Articles 2841-2850  | Next

Colloidal aggregation confounds cell-based Covid-19 antiviral screens
Glenn, I. S., Hall, L. N., Khalid, M. M., Ott, M., Shoichet, B. K.
10.1101/2023.10.27.564435 — Posted: 2023-10-30
Deciphering the code of viral-host adaptation through maximum entropy models
Di Gioacchino, A., Greenbaum, B. D., Monasson, R., Cocco, S.
10.1101/2023.10.28.564530 — Posted: 2023-10-30
Inhalation Delivered RNA Aptamer for Therapeutics against SARS-CoV2
Song, M., Zhou, J., Herrara, A., Bains, P., Rossi, J.
10.1101/2023.10.28.564096 — Posted: 2023-10-30
Characterization of Unique Pathological Features of COVID-Associated Coagulopathy: Studies with AC70 hACE2 Transgenic Mice Highly Permissive to SARS-CoV-2 Infection
Drelich, A. K., Rayavara, K., Hsu, J., Saenkham-Huntsinger, P., Judy, B. M., Tat, V., Ksiazek, T. G., Peng, B.-H., Tseng, C.-T. K.
10.1101/2023.10.30.564680 — Posted: 2023-10-30
NK cell-monocyte crosstalk underlies NK cell activation in severe COVID-19
Lee, M. J., de los Rios Kobara, I., Barnard, T. R., Vales Torres, X., Tobin, N. H., Ferbas, K. G., Rimoin, A. W. J., Yang, O. O., Aldrovandi, G. M., Wilk, A. J., Fulcher, J., Blish, C. A.
10.1101/2023.10.27.564440 — Posted: 2023-10-30
Post-pandemic memory T-cell response to SARS-CoV-2 is durable, broadly targeted and cross-reactive to hypermutated BA.2.86
Nesamari, R., Omondi, M. A., Hoft, M. A., Ngomti, A., Baguma, R., Nkayi, A. A., Besethi, A. S., Magugu, S. F., Mosala, P., Walters, A., Clark, G. M., Mennen, M., Skelem, S., Adriaanse, M., Grifoni, A., Sette, A., Keeton, R. S., Ntusi, N. A., Riou, C., Burgers, W. A.
10.1101/2023.10.28.23297714 — Posted: 2023-10-30
Wastewater Tiling Amplicon Sequencing Reveals Longitudinal Dynamics of SARS-CoV-2 Variants Prevalence in the Community
Wang, Y., Ni, G., Tian, W., Wang, H., Li, J., Thai, P., Choi, P. M., Jackson, G., Hu, S., Yang, B., Guo, J.
10.1101/2023.10.30.23297759 — Posted: 2023-10-30
Complement dysregulation is a predictive and therapeutically amenable feature of long COVID
Baillie, K., Davies, H. E., Keat, S. B. K., Ladell, K., Miners, K. L., Jones, S. A., Mellou, E., Toonen, E. J. M., Price, D. A., Morgan, B. P., Zelek, W. M.
10.1101/2023.10.26.23297597 — Posted: 2023-10-28
Understanding COVID-19 testing behaviour in England through a sociodemographic lens
Bajaj, S., Chen, S., Creswell, R., Naidoo, R., L.-H. Tsui, J., Kolade, O., Nicholson, G., Lehmann, B., A. Hay, J., U.G. Kraemer, M., Aguas, R., A. Donnelly, C., Fowler, T., Hopkins, S., Cantrell, L., Dahal, P., J. White, L., Stepniewska, K., Voysey, M., Lambert, B., EY-Oxford Health Analytics Consortium
10.1101/2023.10.26.23297608 — Posted: 2023-10-28
Mental health conditions and COVID-19 vaccine outcomes: a scoping review
Jia, R., Coupland, C., Vinogradova, Y., Qureshi, N., Turner, E., Vedhara, K.
10.1101/2023.10.27.23297663 — Posted: 2023-10-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).